Abiopharma

🔍 Rasmus Robert E. (Director)

Company: Arq, Inc. (ARQ)

Report Date: 2026-03-23

Detailed Transactions and Holdings:

• Sold 845 shares of Common Stock at $2.27 per share (Direct)
  Date: 2026-03-23 | Code: F | equity_swap_involved: 0 | shares_owned_after: 479,937.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-23 | Code: H | nature_of_ownership: By RER Investments LLC | shares_owned_after: 70,718.00 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-23 | Code: H | nature_of_ownership: By RER Legacy Investments II LLC. | shares_owned_after: 527,779.00 | Footnotes: F3

Footnotes:

• F1: Reflects the withholding of shares of the Issuer's common stock to satisfy tax withholding obligations in connection with the vesting of restricted stock awards ("RSAs") on March 23, 2026.
• F2: The shares of Common Stock reported on this row are held by RER Investments LLC ("RER Investments"). Mr. Rasmus, the Chief Executive Officer and a Director of the Issuer, is the ultimate control person of RER Investments, and an indirect beneficial owner of these shares. Mr. Rasmus disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
• F3: The shares of Common Stock reported on this row are held by RER Legacy Investments II LLC ("RER Legacy"). Mr. Rasmus, the Chief Executive Officer and a Director of the Issuer, is the ultimate control person of RER Legacy, and an indirect beneficial owner of these shares. Mr. Rasmus disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.